Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Roth DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,451Price:$4.95
-
Apr 02, 2024 (filed on Apr 02, 2024)Insider Name:Roth DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-150Price:$4.98
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Stephens KristinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,218Price:$5.12
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Simonian Nancy AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-14,052Price:$5.12
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Roth DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,732Price:$5.12
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Haas JasonOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,732Price:$5.12
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Chee ConleyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,500Price:$5.12
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Stephens KristinOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-11,666Price:--
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Stephens KristinOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,000Price:--
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Stephens KristinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:11,666Price:--
Filings by filing date
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Roth DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,451Price:$4.95
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Stephens KristinOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-11,666Price:--
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Stephens KristinOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,000Price:--
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Stephens KristinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,218Price:$5.12
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Stephens KristinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:11,666Price:--
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Stephens KristinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,000Price:--
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Simonian Nancy AOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-39,566Price:--
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Simonian Nancy AOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-6,000Price:--
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Simonian Nancy AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-14,052Price:$5.12
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Simonian Nancy AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:39,566Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 35 Cambridge Park Drive CAMBRIDGE MA 02140 |
Tel: | N/A |
Website: | https://syros.com |
IR: | See website |
Key People | ||
Conley Chee President, Chief Executive Officer, Director | Jason Haas Chief Financial Officer | Gerald E. Quirk Chief Legal Officer |
David A. Roth Chief Medical Officer | Kristin Stephens Chief Development Officer |
Business Overview |
N/A |
Financial Overview |
For the fiscal year ended 31 December 2023, Syros Pharmaceuticals Inc revenues decreased 33% to $9.9M. Net loss increased 74% to $164.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects FV Adjustments of Financial Investments decrease from $43.2M (income) to $37.3M (expense), Research & Development - Balancing value increase of 1% to $76.7M (expense). |
Employees: | 68 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $36.41M as of Dec 31, 2023 |
Annual revenue (TTM): | $9.94M as of Dec 31, 2023 |
EBITDA (TTM): | -$124.25M as of Dec 31, 2023 |
Net annual income (TTM): | -$164.57M as of Dec 31, 2023 |
Free cash flow (TTM): | -$109.98M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 26,728,337 as of Apr 10, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |